Unleashing Synergy:

Oncolytic Virotherapy and mRNA Vaccines
Unite in the Battle Against Cancer

Virogin Biotech is a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer.

We have developed two platforms: (1) innovative HSV-1 based oncolytic virus and (2) mRNA-based (including self-amplifying RNA/saRNA) therapeutics, aiming to elicit robust and durable anti-tumor immune response against solid tumors.

Both platforms exhibit a high degree of complementarity via a mechanism of Heterologous Prime-Boost. Yet each platform has ‘plug-to-play’ features to independently develop novel therapies against cancer & other indications. This combination approach presents a unique opportunity to elevate tumor vaccine immunotherapy to an unprecedented level.

Our oncolytic HSV-1 platform has two candidates in clinical trials, with our most advanced asset in Phase 2. Candidates from our mRNA platform have also completed preclinical proof of concept.

CAREERS @ VIROGIN

Join our journey and be part of our team! Bring your passion and determination to make a difference in solving one of the world’s biggest challenges—a future without cancer.